- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | Pharmather Holdings Ltd: Pharmather enters obesity market with PharmaPatch | 1 | Stockwatch | ||
| 14.01. | PharmaTher Holdings Ltd.: PharmaTher Expands PharmaPatch Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs | 136 | Newsfile | Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking... ► Artikel lesen | |
| 02.01. | Pharmather Holdings Ltd: Pharmather Holdings CEO recaps 2025 work | 1 | Stockwatch | ||
| 02.01. | PharmaTher Holdings Ltd.: PharmaTher CEO Publishes Letter to Shareholders | 254 | Newsfile | Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published... ► Artikel lesen | |
| 03.12.25 | Pharmather Holdings Ltd: Pharmather closes sale of ketamine ANDA | 3 | Stockwatch | ||
| 02.12.25 | PharmaTher Holdings Ltd.: PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise | 235 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the... ► Artikel lesen | |
| PHARMATHER Aktie jetzt für 0€ handeln | |||||
| 17.11.25 | PharmaTher Holdings Ltd.: PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program | 259 | Newsfile | Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking... ► Artikel lesen | |
| 07.11.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 07.11.2025 | 527 | Xetra Newsboard | The following instruments on XETRA do have their first trading 07.11.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 07.11.2025
Aktien
1 NO0013683821 Appear ASA
2 US30209R1068... ► Artikel lesen | |
| 17.10.25 | PharmaTher Holdings Ltd.: PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale | 455 | Newsfile | Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the... ► Artikel lesen | |
| 17.10.25 | Pharmather Holdings Ltd: Pharmather preparing phase 3 FDA package for ketamine | 2 | Stockwatch | ||
| 16.10.25 | PharmaTher Holdings Ltd.: PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease | 197 | Newsfile | Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the... ► Artikel lesen | |
| 15.10.25 | Pharmather Holdings Ltd: Pharmather touts "discovery platform" KetAImine | 3 | Stockwatch | ||
| 15.10.25 | PharmaTher Holdings Ltd.: PharmaTher Announces KetAImine - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings | 199 | Newsfile | Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the... ► Artikel lesen | |
| 09.10.25 | Pharmather Holdings Ltd: Pharmather talks ketamine as Parkinson's treatment | 2 | Stockwatch | ||
| 08.10.25 | PharmaTher Holdings Ltd.: PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease | 233 | Newsfile | Phase 3 program targeting a potential US$2.2B U.S. market opportunity505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and timeFDA-reviewed CMC package validated through prior... ► Artikel lesen | |
| 02.10.25 | Pharmather Holdings Ltd: Pharmather clarifies sale of one generic ketamine asset | 1 | Stockwatch | ||
| 02.10.25 | PharmaTher Holdings Ltd.: PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy | 234 | GlobeNewswire (Europe) | TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical... ► Artikel lesen | |
| 02.10.25 | Pharmather Holdings Ltd: Pharmather signs definitive deal to sell ketamine ANDA | 1 | Stockwatch | ||
| 01.10.25 | PharmaTher announces sale of Ketamine ANDA | 1 | Seeking Alpha | ||
| 01.10.25 | PharmaTher Holdings Ltd.: PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments | 142 | GlobeNewswire (Europe) | TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,980 | -0,46 % | FDA gibt Netzhaut-Zelltherapie von Bayer-Tochter Orphan-Drug-Status | DJ FDA gibt Netzhaut-Zelltherapie von Bayer-Tochter Orphan-Drug-Status
DOW JONES--Die US-Bayer-Tochter Bluerock hat für ihren Zelltherapie-Kandidaten OpCT-001 von der US-Gesundheitsbehörde FDA... ► Artikel lesen | |
| NOVO NORDISK | 49,670 | -1,76 % | BARCLAYS stuft NOVO NORDISK auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Novo Nordisk auf "Equal Weight" mit einem Kursziel von 360 dänischen Kronen belassen. Die jüngsten Daten zur... ► Artikel lesen | |
| HARROW | 42,610 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,235 | 0,00 % | Block & Leviton LLP: Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation | Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) for potential securities law violations. Investors who have... ► Artikel lesen | |
| MERCK KGAA | 128,20 | +0,91 % | EQS-AFR: Merck KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Merck KGaA
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Merck KGaA: Vorabbekanntmachung über die Veröffentlichung... ► Artikel lesen | |
| SANOFI | 77,46 | +0,53 % | JEFFERIES stuft SANOFI auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Sanofi auf "Buy" mit einem Kursziel von 100 Euro belassen. Sanofi sei trotz des erwarteten branchenüblichen Wachstums bis... ► Artikel lesen | |
| LB PHARMACEUTICALS | 21,240 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program | Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 14,760 | -1,86 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| LIPOCINE | 9,560 | -7,90 % | Lipocine Inc.: Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) | SALT LAKE CITY, Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,940 | -3,48 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia ... | CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay cap for eligible commercially insured... ► Artikel lesen | |
| 60 DEGREES PHARMACEUTICALS | 5,200 | 0,00 % | 60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA for Malaria Prevention | Partnership adds a travel-focused consumer telehealth platform to the ARAKODA marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the worldARAKODA... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 80,45 | -5,35 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| OMNIAB | 1,855 | 0,00 % | OmniAb outlines $18M-$22M 2025 revenue guidance while launching OmniUltra and expanding xPloration platform | ||
| PFIZER | 21,665 | +0,05 % | Dividendenbekanntmachungen (23.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALBERTSONS COMPANIES INC US0130911037 0,15 USD 0,1275 EUR BANK OF NEW YORK MELLON CORPORATION US0640581007 0,53 USD 0,4508 EUR COCA-COLA... ► Artikel lesen | |
| SHUTTLE PHARMACEUTICALS | 2,170 | 0,00 % | Shuttle Pharmaceuticals Holdings Inc.: Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever | Gaithersburg, Maryland--(Newsfile Corp. - January 13, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), applauds the state of Utah which has become... ► Artikel lesen |
Das Unternehmen PHARMATHER HOLDINGS LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,049 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMATHER HOLDINGS LTD finden Sie auf Wallstreet Online.